# Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

> **NCT02351739** · PHASE2 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 78 (actual)

## Conditions studied

- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** ACP-196 in combination with pembrolizumab

## Key facts

- **NCT ID:** NCT02351739
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2018-02
- **Final completion:** 2018-04
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2019-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02351739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02351739, "Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT02351739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*